CJC-1295 — reference
Growth-hormone secretagogue (GHRH analog), often paired with a GHRP like Ipamorelin.
Regulatory status
Not FDA-Approved. Not FDA-approved; research chemical.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of ~6–8 days (with DAC). DAC (Drug Affinity Complex) binds albumin, extending half-life dramatically vs. the no-DAC form.
This figure is tagged PK study in our evidence system. This figure comes from a published pharmacokinetic study rather than a label or registration trial. Sample sizes in such studies are often small and figures vary between them, so treat the number as a range rather than a constant. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is CJC-1295 FDA-approved?
What is the half-life of CJC-1295?
How reliable is that half-life figure?
What cautions are associated with CJC-1295?
Does Peptide Plug publish dosing for CJC-1295?
Does Peptide Plug sell CJC-1295?
Related tools
Free, no account required.